Venus Remedies Limited (NSE: VENUSREM, BSE: 526953) has secured marketing authorization from Argentina’s national regulatory authority for its antibiotic, Ceftriaxone.
The approval marks a significant milestone in the company’s expansion across Latin America, strengthening its growing international portfolio and taking the total marketing authorizations (MAs) for Ceftriaxone to 39 globally.
The development further reinforces Venus Remedies’ commitment to improving access to essential anti-infective therapies while supporting India’s growing role as a reliable supplier of high-quality injectable pharmaceuticals worldwide.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said, “The approval of Ceftriaxone in Argentina represents an important step in strengthening our presence in the Latin American region. Argentina is the fourth-largest pharmaceutical market in Latin America, valued at approximately USD 7.3 billion in 2023, making it a strategically important market for high-quality critical care therapies. Ceftriaxone remains a cornerstone antibiotic in the management of several serious bacterial infections, including meningitis, respiratory tract infections, bloodstream infections, and surgical infections, making it a critical therapy in hospital and intensive care settings. This authorization aligns with our focus on delivering clinically relevant and widely accessible anti-infective therapies across global markets.”
Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, “Securing this marketing authorization in Argentina is a strategically important milestone in our Latin America expansion journey. At Venus Remedies, we remain focused on strengthening our presence in such high-potential markets while supporting the broader agenda of improving access to affordable and quality healthcare solutions globally.”
The approval enables Venus Remedies to commercialize Ceftriaxone in Argentina through its established distribution networks, further strengthening its position in hospital-driven critical care injectable markets.
